News Column

D-Wave Systems Partners with DNA-SEQ Alliance and 1QBit

June 12, 2014

D-Wave Systems adds two new partnerships as part of its application ecosystem.

According to a media release, DNA-SEQ and 1QBit are developing software applications that take advantage of D-Wave's unique quantum computing capabilities.

"Quantum computing will reach its full potential through collaborative partnerships with pioneering organizations like DNA- SEQ and 1QBit, who are working to solve incredibly complex problems," said Vern Brownell, CEO of D-Wave. "Combining our expertise and technology with experts in fields like cancer research and finance is starting to produce remarkable results. From creating more targeted and effective cancer therapies to optimizing financial portfolios, quantum computing applications are already having real impact."

To support the building of an application ecosystem, D-Wave Systems provides access to its quantum computers and the expertise necessary to map specific problems onto its quantum hardware. DNA- SEQ and 1QBit are working closely with D-Wave to develop machine learning and optimization techniques to address critical real-world applications.

DNA-SEQ aims to enable more precisely targeted drug therapies for cancer patients by using 3D precision crystallography, and a patient's full genomic data, to identify early drug resistance and to match their specific mutations to more effective therapies. Existing technology can only analyze small amounts of genomic data, limiting the ability to match a patient's specific mutation to the optimal cancer drug. Ongoing collaborations with the Children's Hospital Los Angeles, Baylor College of Medicine, and the USC Norris Comprehensive Cancer Center are enabling the company to implement its technologies in clinics to identify novel treatments for cancer patients that have developed resistance to therapy. DNA-SEQ has also begun to collaborate with the USCD Pediatric Diabetes Center to implement its technologies in the field of stem cell research.

"Exploring cancer genomics using 3D crystallography and full genomic data enables extraordinary pattern matching of mutations to available drugs, and it is only possible with D-Wave's unique computational machine learning capabilities and our crystal structures libraries," said Dr. Janusz Sowadski, CEO of DNA-SEQ.

More information and complete details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Professional Services Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters